Michael Kragh
Ballerup, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.
Journal: Nature
Published: February 16, 2026
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.
Journal: Scientific reports
Published: September 16, 2019
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: July 02, 2019
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Journal: Theranostics
Published: June 11, 2019
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Journal: Molecular cancer therapeutics
Published: May 02, 2019
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Journal: Science translational medicine
Published: April 26, 2019
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Journal: Breast cancer research : BCR
Published: March 26, 2019
Neonates colonized with pathogenic bacteria in the airways have a low-grade systemic inflammation.
Journal: Allergy
Published: April 09, 2018
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Journal: Journal of neuro-oncology
Published: January 23, 2018
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Journal: International journal of cancer
Published: October 11, 2017
Last Updated: 09/26/2026